Translational Nanotechnology for Improved Cardiovascular Risk Assessment

Project: Research project

Description

Coronary heart disease is the number one killer globally and is responsible for causing heart attacks and angina (heart pain). Although traditional risk factors such as age, smoking status, cholesterol levels, and blood pressure help guide physicians in
understanding who is at risk for developing coronary heart disease, there is no crystal ball, and risk prediction remains imperfect. Thus there is great need to develop additional strategies to help predict who is at risk for developing heart disease so that these patients can get more intensive therapies. The investigator for this project has invented a new test called the AuraChol test. This test harnesses the power of gold nanoparticles one tenthousandth the thickness of a human hair to measure how well highdensity lipoprotein (HDL, or "good cholesterol") functions in patients. This new AuraChol test will be compared to the laboratory standard test, the cellular reverse cholesterol transport assay. Unlike the standard test used in research laboratories, the AuraChol test is rapid (4 hour versus 72 hour turnaround), automatable, and does not depend on tissue culture
techniques or radiochemicals.
StatusFinished
Effective start/end date1/1/1412/31/15

Funding

  • Northwestern Memorial Hospital (NMH02052014/Exhibit B.7)

Fingerprint

Nanotechnology
Cholesterol
Coronary Disease
HDL Lipoproteins
Gold
Hair
Nanoparticles
Heart Diseases
Smoking
Myocardial Infarction
Research Personnel
Blood Pressure
Physicians
Pain
Research
Therapeutics